John W. Newcomer, MD

  • 35Articles
  • 118.2KReads
  • 2001–2023Active
  • 99Collaborators
  • 1.5KCitations

About

John W. Newcomer, MD, is affiliated with Thriving Mind South Florida in Miami and the Department of Psychiatry at Washington University School of Medicine in St. Louis. He has authored 35 articles on topics such as metabolic disorders, schizophrenia, bipolar disorder, and psychiatry, published between 2001 and 2023. His frequent co-authors include Charles H. Hennekens, Dan W. Haupt, Daniel E. Casey, Michael J. Sernyak, and David C. Henderson.

Publications

JCP
Brexpiprazole in Patients With MDD and Prediabetes
Original Research

Brexpiprazole in Patients With MDD and Prediabetes

August 28, 2023

Some atypical antipsychotics, while efficacious as adjunctive treatments in major depressive disorder (MDD), can lead to adverse effects and weight gain. Adjunctive brexpiprazole had a limited impact on metabolic...
, , , et al
JCP
Original Research

Response to Subcutaneous Injectable Monthly Risperidone (RBP-7000): PANSS Item-Level Analysis

September 21, 2021

Phase 3 study data on the efficacy of RBP-7000 for schizophrenia were examined to see if dose-response relationships exist for different items of the Positive and Negative Syndrome Scale.
, , , et al
JCP
Consensus Statement

Consensus on Monitoring Blood Antipsychotic Levels

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
, , , et al
JCP
Original Research

Brexpiprazole in MDD—Metabolic Parameters and Weight

October 1, 2019

Adjunctive atypical antipsychotics can increase antidepressant response in depressed patients, but may cause adverse metabolic effects. This study examines the metabolic effects of adjunctive brexpiprazole in patients with major...
, , , et al
JCP
Original Research

Metabolic Effects of Aripiprazole Lauroxil

November 23, 2016

Aripiprazole lauroxil, a long-acting injectable antipsychotic, demonstrated safety and efficacy in treating schizophrenia symptoms in a recent RCT. But how does it stack up against other antipsychotics in terms...
, , , et al
JCP
Academic Highlights

Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice

October 23, 2013

, ,
JCP
Review Article

Changes in Weight, Plasma Lipids, and Glucose in Adults Treated With Ziprasidone: A Comprehensive Analysis of Pfizer-Initiated Clinical Trials

June 15, 2012

, ,
JCP
Article

Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients With Comorbid Medical Illnesses

June 25, 2009

JCP
Original Research

A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone

April 7, 2009

, , , et al
JCP
Original Research

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

July 31, 2008

, , , et al
JCP
Original Research

Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges

March 18, 2008

, , , et al
JCP
Original Research

Prevalence of Baseline Serum Glucose and Lipid Testing in Users of Second-Generation Antipsychotic Drugs: A Retrospective, Population-Based Study of Medicaid Claims Data

February 14, 2008

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe